Our base case of Q3 marking the low point remains
Bactiguard’s Q3 results were overall on the weak side, negatively impacted by lower consumption of catheters because of general healthcare put on hold and increased focus on treating COVID-19 patients. However, commentary regarding strong order intake at the end of Q3 and at the beginning of Q4 from BD, combined with our expected Well Lead contribution in Q4 (no orders YTD), reinforce our view that Q3 will mark the low point.
LÄS MER
